Menu Search
Equities

Mabpharm Ltd

2181:HKG.HZ

Mabpharm Ltd

Actions
  • Price (HKD)0.375
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-36.44%
  • Beta--
Data delayed at least 15 minutes, as of May 14 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Mabpharm Ltd is China-based company mainly engaged in the research, development and production of monoclonal antibody drugs for cancers and autoimmune diseases. The Company's main products include omalizumab (CMAB007), cetuximab (CMAB009) and infliximab (CMAB008). The Company mainly conducts its businesses in China market.

  • Revenue in HKD (TTM)94.14m
  • Net income in HKD-226.12m
  • Incorporated2018
  • Employees347.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.